White Pine Capital LLC Has $253,000 Holdings in Teva Pharmaceutical Industries Limited (TEVA)

White Pine Capital LLC cut its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 6.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,617 shares of the company’s stock after selling 500 shares during the period. White Pine Capital LLC’s holdings in Teva Pharmaceutical Industries Limited were worth $253,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Bronfman E.L. Rothschild L.P. raised its stake in Teva Pharmaceutical Industries Limited by 7.8% during the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock worth $116,000 after purchasing an additional 261 shares during the period. Kistler Tiffany Companies LLC raised its stake in Teva Pharmaceutical Industries Limited by 74.7% during the second quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock worth $122,000 after purchasing an additional 1,571 shares during the period. FNY Managed Accounts LLC purchased a new position in Teva Pharmaceutical Industries Limited during the first quarter worth about $123,000. Sterling Investment Advisors Ltd. raised its stake in Teva Pharmaceutical Industries Limited by 2.6% during the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock worth $125,000 after purchasing an additional 100 shares during the period. Finally, Cutler Capital Management LLC purchased a new position in Teva Pharmaceutical Industries Limited during the second quarter worth about $133,000. 56.87% of the stock is currently owned by institutional investors.

A number of brokerages have commented on TEVA. Vetr downgraded shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating and set a $31.05 target price on the stock. in a research note on Thursday, June 22nd. Cantor Fitzgerald set a $31.00 target price on shares of Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a research note on Thursday, June 22nd. BidaskClub downgraded shares of Teva Pharmaceutical Industries Limited from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 16th. BTIG Research raised shares of Teva Pharmaceutical Industries Limited from a “neutral” rating to a “buy” rating and set a $24.00 target price on the stock in a research note on Monday. Finally, Citigroup Inc. downgraded shares of Teva Pharmaceutical Industries Limited from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $32.00 to $19.00 in a research note on Wednesday, August 16th. Five research analysts have rated the stock with a sell rating, nineteen have given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Teva Pharmaceutical Industries Limited presently has an average rating of “Hold” and an average target price of $33.32.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Markets Daily and is owned by of Markets Daily. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright laws. The original version of this piece of content can be read at https://www.themarketsdaily.com/2017/09/11/white-pine-capital-llc-has-253000-holdings-in-teva-pharmaceutical-industries-limited-teva.html.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded up 16.71% on Monday, reaching $18.09. 31,834,610 shares of the company’s stock traded hands. The firm’s market capitalization is $18.38 billion. Teva Pharmaceutical Industries Limited has a 52 week low of $15.22 and a 52 week high of $52.66. The stock has a 50-day moving average of $20.66 and a 200 day moving average of $29.07.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The firm had revenue of $5.69 billion during the quarter, compared to analyst estimates of $5.72 billion. During the same period last year, the business earned $1.25 EPS. The firm’s revenue was up 12.9% compared to the same quarter last year. On average, equities analysts expect that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th will be given a $0.085 dividend. This represents a $0.34 annualized dividend and a yield of 2.19%. The ex-dividend date is Friday, August 25th. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is -15.36%.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply